Clinical trial · Interventional
GYNecologic Cancer-Related COGnitive Impairment
A Pilot and Mixed-Methods Study of GYNecologic Cancer-Related COGnitive Impairment
NCT06662435CI-TRIAL-00106173GYNCOGcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to test a home-based and patient-tailored cognitive training intervention among gynecologic cancer patients who have completed chemotherapy and who have experienced cancer-related cognitive impairment.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancers | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Cervix Cancer | — | UNRESOLVED | — |
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Ovary Cancer | — | UNRESOLVED | — |
| Uterine Cancer | Malignant Uterine Neoplasm | ALIAS | 0.90 |
| Vulvar Cancers | Malignant Vulvar Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GYNCOG | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- GYNCOG Intervention
- description
- Participants in the GYNCOG arm will be asked to participate in a home-based cognitive training program utilizing BrainHQ on study-provided tablets.
- interventionNames
- Behavioral: GYNCOG
- type
- NO_INTERVENTION
- label
- Control Group
- description
- Patients in the Control Group arm will receive usual care with no cognitive intervention.
Primary outcomes (2)
- measure
- Assessment Compliance
- timeFrame
- 20 weeks
- description
- Assessment compliance will be defined as completing the cognitive assessments at baseline and at 10 weeks. The study will be considered feasible in terms of assessment compliance if at least 65% of all patients are compliant.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female; ≥18 years of age * Presents to clinic with a confirmed diagnosis of a gynecologic cancer (e.g., ovarian, endometrial, cervical, or vulvar cancer) who have completed adjuvant chemotherapy with at least stable disease at time of screening. * Screen positive for subjective cognitive impairment by answering affirmatively to at least one of three screener questions * Fluent in spoken and written English * Have access to the internet to complete assessments Exclusion Criteria: * Patients who have not received chemotherapy * Patients with pre-existing neuropsychiatric disorders that would impact cognitive function, such as dementia, Alzheimer's disease, and schizophrenia. * Patients with non-gynecologic causes of incurable metastatic cancers. * Patients undergoing active interventions in other cognitive trials or patients currently using cognitive training programs such as Brain HQ, Luminosity, Elevate, Peak, Fit Brains, or CogniFit. * Patients with self-report of learning disability or an unwillingness to participate in technology-based cognitive training programs. * Pregnant women or prisoners * Patients with impaired-decision making capacity
References
Publications (1)
- DERIVEDWang CC, Kildee I, Reasner E, Bednorski I, Ma YA, Duggan B, Silberman J, Grace A, Kocherginsky M, Barber EL. Feasibility, adherence, and patient experiences in a pilot randomized trial of home-based cognitive training intervention for gynecologic cancer-related cognitive impairment. Gynecol Oncol. 2026 Aug 7;212:64-71. doi: 10.1016/j.ygyno.2026.08.001. Online ahead of print. PMID 42567117